What Davis-Standard will be showcasing at Medtec China

Extrusion and converting technology provider,?Davis-Standard,?will market the company?s line of medical tubing solutions at Medtec China. ?

Medtec China will be held in Shanghai, which is close to Davis-Standard?s manufacturing facilities in Suzhou. Davis-Standard will be showcasing complete systems which have been manufactured in the United States (US), as well as extruders which have been designed in the US and then fabricated locally at Davis-Standard?s subsidiary Davis-Standard (Suzhou) Plastic Packaging Machinery Company.?

The company supplies complete systems for a variety of tubing applications such as single lumen, multi-lumen, coextruded and Alternate Polymer products. This technology supports multiple applications such as those for catheter tubing, endotracheal and tracheotomy tubing, radio opaque tubing, bump and taper tuber and pipette tubing. All tubing systems are produced and supported by Davis-Standard?s headquarters in Pawcatuck, Connecticut.

Davis-Standard claim that all extruders sold in China are engineered and assembled to the same specifications and with the same components as US-based machines but offer the advantages of localised support and fast delivery.

The extruders can be purchased individually or retrofitted to existing lines to improve outputs, stabilise pressure and melt, and optimise the mixing of all thermoplastic resins. In order to achieve the optimal strategy for high line speeds and product tolerance based on application, Davis-Standard engineers work directly with their customers.

An additional benefit of the Suzhou facility is that Chinese customers are able to take advantage of RMB transactions for US designed equipment without import fees, long transit times, and international shipment costs.

The company will be on booth R201 during Medtec China?from September 25th to 27th in Shanghai, China.

Tags Medtec China Extrusion Davis-Standard Tubing run-of-site

» More Information

« Go to Technological Watch

This project has received funding from the Bio-Based Industries Joint Undertaking under the European Union’s Horizon 2020 research and innovation programme under grant agreement Nº 745828